China Shineway Pharmaceutical Group Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2023. The Group's profit attributable to the owners of the Company for the year ended 31 December 2023 (the "Year") is expected to increase by approximately 30% to 36% as compared with that for the corresponding period of last year (2022: RMB 722,773,000). The expected increase in the profit attributable to the owners of the Company for the Year is mainly attributable to the increase in overall sales revenue of the Group of approximately 14% and the decrease in the selling and distribution costs to revenue ratio of approximately 2 to 3 percentage points, as compared with that of last year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.89 HKD | +1.44% | +7.15% | +36.04% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.04% | 943M | |
+22.69% | 43.81B | |
+24.92% | 23.01B | |
+18.00% | 15.27B | |
+8.91% | 13.68B | |
+42.72% | 11.96B | |
-7.21% | 6.98B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.22% | 5.59B |
- Stock Market
- Equities
- 2877 Stock
- News China Shineway Pharmaceutical Group Limited
- China Shineway Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023